Health Canada has approved Ocrevus for children 10 and older with relapsing-remitting MS, expanding treatment options for ...

Trial data suggest a single infusion of the experimental CAR T-cell therapy zola-cel may stabilize disability in relapsing or ...

Early treatment with vidofludimus calcium may lead to less long-term disability in people with progressive forms of MS, data ...

Greater physical disability is associated with cognitive problems in people with multiple sclerosis, according to a review ...

Physical activity programs for people with MS appear feasible and well received, but more research is needed on their use in ...

A Phase 2 trial found that a lower dose of nasal foralumab significantly reduced brain inflammation markers in people with nonactive SPMS.

New Phase 3 data show fenebrutinib reduced markers of chronic brain inflammation in both relapsing forms of MS and primary ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit A review reveals that current evidence does not establish a gluten-free diet as an effective ...

Phase 3 trials show the experimental oral therapy remibrutinib significantly reduced relapse rates and brain lesion activity compared with Aubagio in relapsing multiple sclerosis. The treatment ...

Vaccine fatigue' rose in MS after the COVID-19 pandemic; many patients lacked the protection they thought they had, a German ...